SCHEMBL29400652

SCHEMBL29400652

CC(C)(C)OC(=O)Nc1cc(Cl)ncn1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GSK3B P49841 1/20 0.43
DYRK1A Q13627 1/20 0.43
MKNK2 Q9HBH9 1/20 0.42
MAP4K4 O95819 1/20 0.42
FGFR4 P22455 1/20 0.41
AAK1 Q2M2I8 4/20 0.40
CDK1 P06493 1/20 0.40
EGFR P00533 2/20 0.40
SRC P12931 1/20 0.40
PTGER1 P34995 2/20 0.39
CYP2C9 P11712 1/20 0.38
NPC1 O15118 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
AURKB Q96GD4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18805591 1.00 ATR (0.45) ATRL3MBTL1GSK3BDYRK1AMKNK2
SCHEMBL4664375 0.84 NPC1 (0.53) MAP4K4CDK1EGFRSRCNPC1
SCHEMBL12705673 0.84 GAA (0.43) ATRL3MBTL1MAP4K4FGFR4AAK1
SCHEMBL17265777 0.84 EGFR (0.42) ATRGSK3BDYRK1AMKNK2MAP4K4
SCHEMBL690643 0.84 CDK1 (0.49) MAP4K4FGFR4CDK1EGFRSRC
SCHEMBL18814953 0.84 L3MBTL1 (0.49) ATRL3MBTL1GSK3BDYRK1AMKNK2
SCHEMBL19890987 0.84 L3MBTL1 (0.44) ATRL3MBTL1GSK3BDYRK1AMKNK2
SCHEMBL18805592 0.84 L3MBTL1 (0.68) ATRL3MBTL1GSK3BDYRK1AMKNK2
SCHEMBL10288086 0.83 GSK3B (0.54) ATRGSK3BDYRK1AMAP4K4PTGER1
SCHEMBL691488 0.83 CDK1 (0.48) MAP4K4FGFR4CDK1EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025022007-A1 PESTICIDALLY ACTIVE QUINAZOLINE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2025-01-30 WO disclosed
US-20240417405-A1 Substituted Spiro Derivatives JANSSEN PHARMACEUTICA NV (BE) 2024-12-19 US disclosed
WO-2024159094-A1 PYRIMIDINYL (HETERO)AROMATIC AMINOPYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES ENLIVEN INC. (US) 2024-08-02 WO disclosed
US-20240092799-A1 MNK INHIBITORS HEPAGENE THERAPEUTICS HK LTD (CN) 2024-03-21 US disclosed
EP-4200296-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (HK) 2023-06-28 EP disclosed
WO-2022038563-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (CN) 2022-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092799-A1 MNK INHIBITORS MKNK1, MATK, NEK1 ATR 429/4885L3MBTL1 1524/4885GSK3B 1232/4885
US-20240417405-A1 Substituted Spiro Derivatives BMI1, MLLT1, MLLT3 ATR 1004/4885L3MBTL1 1712/4885GSK3B 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.